Abstract
Agmatine is an amine that is formed by decarboxylation of L-arginine by the enzyme arginine decarboxylase (ADC) and hydrolyzed by the enzyme agmatinase to putrescine. Agmatine binds to several target receptors in the brain and has been proposed as a novel neuromodulator. In animal studies, agmatine potentiated morphine analgesia and reduced dependence/withdrawal. While the exact mechanism is not clear, the interactions with N-methyl-D-aspartate (NMDA) receptors, α2-adrenergic receptors, and intracellular cyclic adenosine monophosphate (cAMP) signaling have been proposed as possible targets. Like other monoamine transmitter molecules, agmatine is rapidly metabolized in the periphery and has poor penetration into the brain, which limits the use of agmatine itself as a therapeutic agent. However, the development of agmatinase inhibitors will offer a useful method to increase endogenous agmatine in the brain as a possible therapeutic approach to potentiate morphine analgesia and reduce dependence/ withdrawal. This review provides a succinct discussion of the biological role/therapeutic potential of agmatine during morphine exposure/pain modulation, with an extensive amount of literature cited for further details.
Similar content being viewed by others
References
Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. Agmatine: an endogenous clonidine-displacing substance in the brain.Science. 1994;263:966–969.
Piletz JE, chikkala DN, Ernsberger P. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors.J Pharmacol Exp Ther. 1995;272:581–587.
Pinthong D, Hussain JF, Kendall DA, Wilson VG. Comparison of the interaction of agmatine and crude methanolic extracts of bovine lung and brain with alpha 2-adrenoceptor binding sites.Br J Pharmacol. 1995;115:689–695.
Pinthong D, Wright IK, Hanmer C, et al. Agmatine recognizes alpha 2-adrenoceptor binding sites but neither activates nor inhibits alpha 2-adrenoceptors.Naunyn Schmiedebergs Arch Pharmacol. 1995;351:10–16.
Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brain?Trends Pharmacol Sci. 2000;21:187–193.
Wang H, Regunathan S, Youngson C, Bramwell S, Reis DJ. An antibody to agmatine localizes the amine in bovine adrenal chromaffin cells.Neurosci Lett. 1995;183:17–21.
Otake K, Ruggiero DA, Regunathan S, Wang H, Milner TA, Reis DJ. Regional localization of agmatine in the rat brain: an immunocytochemical study.Brain Res. 1998;787:1–14.
Yang X-C, Reis DJ. Agmatine selectively blocks the NMDA subclass of glutamate receptor channels in cultured mouse hippocampal neurons.J Pharmacol Exp Ther. 1999;288:544–549.
Gorbatyuk OS, Milner TA, Wang G, Regunathan S, Reis DJ. Localization of agmatine in vasopressin and oxytocin neurons of the rat hypothalamic paraventricular and supraoptic nuclei.Exp Neurol. 2001;171:235–245.
Li G, Regunathan S, Reis DJ. Agmatine is synthesized by a mitochondrial arginine decarboxylase in rat brain.Ann NY Acad Sci. 1995;763:325–329.
Lortie MJ, Novotny WF, Peterson OW, et al. Agmatine, a bioactive metabolite of arginine.J Clin Invest. 1996;97:413–420.
Zhu MY, Iyo A, Piletz JE, Regunathan S. Expression of human arginine decarboxylase, the biosynthetic enzyme for agmatine.Biochim Biophys Acta. 2004;1670:156–164.
Sastre M, Regunathan S, Reis DJ. Agmatinase activity in rat brain: a metabolic pathway for the degradation of agmatine.J Neurochem. 1996;67:1761–1765.
Holt A, Baker GB. Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors.Prog Brain Res. 1995;106:187–197.
Olmos G, DeGregorio-Rocasolano N, Regalado MP, et al. Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor.Br J Pharmacol. 1999;127:1317–1326.
Zhu MY, Piletz JE, Halaris A, Regunathan S. Effect of agmatine against cell death induced by NMDA and glutamate in neurons and PC12 cells.Cell Mol Neurobiol. 2003;23:865–872.
Gilad GM, Gilad VH. Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats.Neurosci Lett. 2000;296:97–100.
Gilad GM, Gilad VH, Rabey JM. Arginine and ornithine decarboxylation in rodent brain—coincidental changes during development and after ischemia.Neurosci Lett. 1996;216:33–36.
Kim JH, Yenari MA, Giffard RG, Cho SW, Park KA, Lee JE. Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury.Exp Neurol. 2004;189:122–130.
Fairbanks CA, Schreiber KL, Brewer KL, et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury.Proc Natl Acad Sci USA. 2000;97:10584–10589.
Feng Y, Piletz JE, Leblanc MH. Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats.Pediatr Res. 2002;52:606–611.
Bence AK, Worthen DR, Stables JP, Crooks PA. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine.Pharmacol Biochem Behav. 2003;74:771–775.
Su RB, Wei XL, Zheng JQ, Liu Y, Lu XQ, Li J. Anticonvulsive effect of agmatine in mice.Pharmacol Biochem Behav. 2004;77:345–349.
Aricioglu F, Kan B, Yillar O, Korcegez E, Berkman K. Effect of agmatine on electrically and chemically induced seizures in mice.Ann NY Acad Sci. 2003;1009:141–146.
Kolesnikov Y, Jain S, Pasternak GW. Modulation of opioid analgesia by agmatine.Eur J Pharmacol. 1996;296:17–22.
Aricioglu-Kartal F, Uzbay IT. Inhibitory effect of agmatine on naloxane-precipitated abstinence syndrome.Life Sci. 1997;61:1775–1781.
Fairbanks CA, Brewer KL, Stone LS, et al. The behavioral and neuroprotective effects of agmatine in different models of pain and neuronal injury in rodents.Soc Neurosci Abstr. 1998;24:1253.
Li J, Li X, Pei G, Qin BY. Agmatine inhibited tolerance to and dependence on morphine in guinea pig ileum in vitro.Zhongguo Yao Li Xue Bao. 1998;19:564–568.
Nguyen HO, Goracke-Postle CJ, Kaminski LL, Overland AC, Morgan AD, Fairbanks CA. Neuropharmacokinetic and dynamic studies of agmatine (decarboxylated arginine).Ann NY Acad Sci. 2003;1009:82–105.
Arteni NS, Lavinsky D, Rodrigues AL, Frison VB, Netto CA. Agmatine facilitates memory of an inhibitory avoidance task in adult rats.Neurobiol Learn Mem. 2002;78:465–469.
Lavinsky D, Arteni NS, Netto CA. Agmatine induces anxiolysis in the elevated plus maze task in adult rats.Behav Brain Res. 2003;141:19–24.
Zomkowski AD, Hammes L, Calixto JB, Lin J, Santos AR, Rodrigues AL. Agmatine produces antidepressant-like effects in two models of depression in mice.Neuroreport. 2002;13:387–391.
Sauve Y, Reader TA. Effects of alpha-methyl-p-tyrosine on monoamines and catecholamine receptors in rat cerebral cortex and neostriatum.Neurochem Res. 1988;13:807–815.
Dias Elpo Zomkowski A, Oscar Rosa A, Lin J, Santos AR, Calixto JB, Lucia Severo Rodrigues A. Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test.Brain Res. 2004;1023:253–263.
Li J, Li X, Pei G, Qin BY. Effects of agmatine on tolerance to and substance dependence on morphine in mice.Zhongguo Yao Li Xue Bao. 1999;20:232–238.
Uzbay IT, Yesilyurt O, Celik T, Ergun H, Isimer A. Effects of agmatine on ethanol withdrawal syndrome in rats.Behav Brain Res. 2000;107:153–159.
Aricioglu F, Means A, Regunathan S. Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system.Eur J Pharmacol. 2004;504:191–197.
Aricioglu F, Paul IA, Regunathan S. Agmatine reduces only peripheral-related behavioral signs, not the central signs, of morphine withdrawal in nNOS deficient transgenic mice.Neurosci Lett. 2004;354:153–157.
Morgan AD, Campbell UC, Fons RD, Carroll ME. Effects of agmatine on the escalation of intravenous cocaine and fentanyl self-administration in rats.Pharmacol Biochem Behav. 2002;72:873–880.
Aricioglu F, Korcegez E, Bozkurt A, Ozyalcin S. Effect of agmatine on acute and mononeuropathic pain.Ann N Y Acad Sci. 2003;1009:106–115.
Onal A, Delen Y, Ulker S, Soykan N. Agmatine attenuates neuropathic pain in rats: possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum.Life Sci. 2003;73:413–428.
Yu CG, Fairbanks CA, Wilcox GL, Yezierski RP. Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats.J Pain 2003;4:129–140.
Santos AR, Gadotti VM, Oliveira GL, et al. Mechanisms involved in the antinociception caused by agmatine in mice.Neuropharmacology. 2005;48:1021–1034.
Bradley KJ, Headley PM. Effect of agmatine on spinal nociceptive reflexes: lack of interaction with alpha2-adrenoceptor or mu-opioid receptor mechanisms.Eur J Pharmacol. 1997;331:133–138.
Reynolds IJ. Arcaine uncovers dual interactions of polyamines with the n-methyl-d-aspartate receptor.J Pharmacol Exp Ther. 1990;255:1001–1007.
Gibson DA, Harris BR, Rogers DT, Littleton JM. Radioligand binding studies reveal agmatine is a more selective antagonist for a polyamine-site on the NMDA receptor than arcaine or ifenprodil.Brain Res. 2002;952:71–77.
Askalany AR, Yamakura T, Petrenko AB, Kohno T, Sakimura K, Baha H. Effect of agmatine on heteromeric N-methyl-d-aspartate receptor channels.Neurosci Res. 2005;52:387–392.
Trujillo KA, Akil H. Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists.Brain Res. 1994;633:178–188.
Jurkiewicz NH, do Carmo LG, Hirata H, da Costa Santos W, Jurkiewicz A. Functional properties of agmatine in rat vas deferens.Eur J Pharmacol. 1996;307:299–304.
Gatti PJ, Hill KJ, Da Silva AM, Norman WP, Gillis RA. Central nervous system site of action for the hypotensive effect of clonidine in the cat.J Pharmacol Exp Ther. 1988;245:373–380.
Hansson BG, Hokfelt B. Changes in blood pressure, plasma catecholamines and plasma renin activity during and after treatment with tiamenidine and clonidine.Br J Clin Pharmacol. 1981;11:73–77.
Hieble JP, Kolpak DC. Mediation of the hypotensive action of systemic clonidine in the rat by alpha 2-adrenoceptors.Br J Pharmacol. 1993;110:1635–1639.
Sun MK, Regunathan S, Reis DJ. Cardiovascular responses to agmatine, a clonidine-displacing substance, in anesthetized rat.Clin Exp Hypertens. 1995;17:115–128.
Szabo B, Urban R, Limberger N, Starke K. Cardiovascular effects of agmatine, a “clonidine-displacing substance”, in conscious rabbits.Naunyn Schmiedebergs Arch Pharmacol. 1995;351:268–273.
Raasch W, Schafer U, Qadri F, Dominiak P. Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction.Br J Pharmacol. 2002;135:663–672.
Tokuyama S, Zhu H, Oh S, Ho IK, Yamamoto T. Further evidence for a role of NMDA receptors in the locus coeruleus in the expression of withdrawal syndrome from opioids.Neurochem Int. 2001;39:103–109.
Wang G, Gorbatyuk O, Dayanithi G, et al. Evidence for endogenous agmatine in hypothalamo-neurohypophysial tract and its modulation on vasopressin release and Ca2+ channels.Brain Res. 2002;932:25–36.
Zheng JQ, Weng XC, Gai XD, Li J, Xiao WB. Mechanism underlying blockade of voltage-gated calcium channels by agmatine in cultured rat hippocampal neurons.Acta Pharmacol Sin. 2004;25:281–285.
Feng Y, Leblanc MH, Regunathan S. Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects.Neurosci Lett. 2005;390:129–133.
Regunathan S, Youngson C, Raasch W, Wang H, Reis DJ. Imidazoline receptors and agmatine in blood vessels: a novel system inhibiting vascular smooth muscle proliferation.J Pharmacol Exp Ther. 1996;276:1272–1282.
Satriano J, Matsufuji S, Murakami Y, et al. Agmatine suppresses proliferation by frameshift induction of antienzyme and attenuation of cellular polyamine levels.J Biol Chem. 1998;273:15313–15316.
Abe K, Abe Y, Saito H. Agmatine suppresses nitric oxide production in microglia.Brain Res. 2000;872:141–148.
Satriano J, Schwartz D, Ishizuka S, et al. Suppression of inducible nitric oxide generation by agmatine aldehyde: beneficial effects in sepsis.J Cell Physiol. 2001;188:313–320.
Regunathan S, Piletz JE. Regulation of inducible nitric oxide synthase and agmatine synthesis in macrophages and astrocytes.Ann NY Acad Sci. 2003;1009:20–29.
Li J, Li X, Pei G, Qin BY. Influence of agmatine in adaptation of cAMP signal transduction system of opiate receptors.Zhongguo Yao Li Xue Bao. 1999;20:592–596.
Nestler EJ. Molecular neurobiology of addiction.Am J Addict. 2001;10:201–217.
Copeland RL, Pradhan SN, Dillon-Carter O, Chuang DM. Rebound increase of basal cAMP level in NG108-15 cells during chronic morphine treatment: effects of naloxane and chloramphenicol.Life Sci. 1989;44:1107–1116.
Mehta CS, Strada SJ. Effects of acute and continuous administration of morphine on the cAMP response induced by norepinephrine in rat brain slices.Life Sci. 1994;55:35–42.
Avidor-Reiss T, Bayewitch M, Levy R, Matus-Leibovitch N, Nevo I, Vogel Z. Adenylylcyclase supersensitization in mu-opioid receptortransfected Chinese hamster ovary cells following chronic opioid treatment.J Biol Chem. 1995;270:29732–29738.
Guitart X, Nestler EJ. Second messenger and protein phosphorylation mechanisms underlying opiate addiction: studies in the rat locus coeruleus.Neurochem Res. 1993;18:5–13.
Lane-Ladd SB, Pineda J, Boundy VA, et al. CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence.J Neurosci. 1997;17:7890–7901.
Feng Y, Leblanc MH. Effect of agmatine on the time course of brain inflammatory cytokines after injury in rat pups.Ann NY Acad Sci. 2003;1009:152–156.
Halaris A, Zhu H, Feng Y, Piletz JE. Plasma agmatine and platelet imidazoline receptors in depression.Ann NY Acad Sci. 1999;881:445–451.
Aricioglu-Kartal F, Regunathan S. Effect of chronic morphine treatment on the biosynthesis of agmatine in rat brain and other tissues.Life Sci. 2002;71:1695–1701.
Iyo AH, Zhu MY, Ordway GA, Regunathan S. Expression of arginine decarboxylase in brain regions and neuronal cells.J Neurochem. 2006;96:1042–1050.
Fairbanks CA, Kaminski LL, Nguyen HO, et al. Pretreatment with antisera raised against agmatine sensitizes mice to plasticity-mediated events [abstract].Soc Neurosci Abstr [serial online]. 2001;27.
Vanderah TW, Wild KD, Takemori AE, et al. Modulation of morphine antinociception by swim-stress in the mouse: involvement of supraspinal opioid delta-2 receptors.J Pharmacol Exp Ther. 1993;267:449–455.
Huang M-J, Regunathan S, Botta M, et al. Structure-activity analysis of guanidine group in agmatine for brain agmatinase.Ann NY Acad Sci. 2003;1009:52–63.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published: July 21, 2006
Rights and permissions
About this article
Cite this article
Regunathan, S. Agmatine: Biological role and therapeutic potentials in morphine analgesia and dependence. AAPS J 8, 56 (2006). https://doi.org/10.1208/aapsj080356
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/aapsj080356